Pfizer (PFE) Accumulated Expenses (2009 - 2026)

Pfizer has disclosed Accumulated Expenses across 18 years of filings, most recently posting $2.7 billion for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 4.14% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $2.7 billion (up 4.14% YoY), while the FY2025 annual figure was $3.6 billion, down 5.94% from the prior year.
• Accumulated Expenses fell to $2.7 billion in Q1 2026, from $3.6 billion in the prior quarter.
• Over the last five years, Accumulated Expenses for PFE reached as high as $3.8 billion in Q4 2024 and fell as low as $2.0 billion in Q3 2023.
• The 5-year median for Accumulated Expenses is $2.6 billion (2025), against an average of $2.7 billion.
• Annual changes were most pronounced in 2023 — Accumulated Expenses retreated 18.52% — and 2024, when it surged 42.62%.
• A 5-year view of Accumulated Expenses shows it stood at $3.4 billion in 2022, then slipped by 18.52% to $2.8 billion in 2023, then surged by 38.26% to $3.8 billion in 2024, then declined by 5.94% to $3.6 billion in 2025, then declined by 24.79% to $2.7 billion in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.7 billion, $3.6 billion, and $3.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.